表紙
市場調査レポート

世界の非侵襲的出生前診断市場

The Global Non-Invasive Prenatal Diagnostics Market

発行 Veracity Health 商品コード 309760
出版日 ページ情報 英文 108 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
世界の非侵襲的出生前診断市場 The Global Non-Invasive Prenatal Diagnostics Market
出版日: 2014年07月28日 ページ情報: 英文 108 Pages
概要

当レポートでは、世界の非侵襲的出生前診断の市場について調査し、出生前診断の非侵襲的手法として用いられる新しいバイオマーカーにおける血中循環無細胞DNA、DNA、mRNAの利用の動向、非侵襲的出生前診断市場の地域・主要国別の収益予測および市場シェア分析、市場成長への影響因子の分析、産業への脅威・課題の分析、主要事業者のプロファイルなどをまとめています。

エグゼクティブサマリー

第1章 非侵襲的出生前診断市場について

  • 本書の背景
  • 本書の目的・提供内容
  • 調査手法

第2章 血中循環核酸(CNA:Circulating Nucleic Acids)の背景

  • 血中循環核酸について
  • 血中循環核酸のカテゴリー
    • 血中循環無細胞DNA
    • 血中循環胞外DNA
    • RNA
      • microRNA(miRNA)
      • miRNA模倣体・阻害剤
      • siRNA(Small Interfering RNA)
      • RNAi(RNA Interference)
  • 診断ツールとしての血中循環核酸
    • 癌バイオマーカーとしての血中循環DNA
    • 出生前診断での血中循環DNAの利用
    • 癌バイオマーカーとしての血中循環RNA
    • 妊娠中の血中循環RNA
  • 血中循環核酸の検出に用いられる手法

第3章 市場収益分析:非侵襲的出生前診断

  • イントロダクション
  • 市場力学
    • 市場成長推進因子
  • 主な非侵襲的出生前診断製品
  • 市場収益分析
    • 世界市場の収益分析
    • 世界市場の収益分析:地域別
    • 市場収益分析:国別

第4章 市場シェア分析:非侵襲的出生前診断

  • 市場シェア分析
    • 世界市場シェア分析
    • 市場シェア分析:地域別
    • 市場シェア分析:主要国別

第5章 企業プロファイル

  • Sequenom Inc
  • Ariosa Diagnostics
  • Natera Inc
  • LifeCodexx AG
  • Verinata Health, Inc(Illumina, Inc)
  • Berry Genomics Co., Ltd
  • BGI Diagnostics(Division of BGI)
  • CellScape
  • Kellbenx
目次

ES.1 Introduction to the Non-invasive Prenatal Diagnostics Market

The aim of this report was to review recent advances in use of circulating cell-free miRNA, DNA and mRNA as novel biomarkers which can be used as a non-invasive method for prenatal diagnostics. The report will also provide a market analysis of the market value, growth rates and market development as well as examining the dynamics and factors influencing the growth and development of this market. This report also looks at the challenges and potential threats facing the industry, and the factors influencing the market shares of the major market suppliers as well as smaller indigenous manufacturers in local markets.

The data collection and forecasting methods used in the preparation of this report are broadly divided into three methods. These are primary data and information gathering, secondary data and information gathering and market share analysis and market forecast prediction. Information and data including estimates on market values, growth rates and market share data were gathered from the methods described and were incorporated into proprietary computer forecasting and market share analysis models.

The forecast model was used to derive market estimates for future years. It incorporates a rate factor, which helps determine the speed with which the market develops, which is similar to that observed for markets for other medical products and is adjusted to match historic data for the market under analysis

ES.2 Background to Circulating Nucleic Acids

This chapter reviews the historical developments that have excited researchers and clinicians alike illustrating the practical applications for elevated CNA levels for the detection of cancer and identifying the different categories or types of CNAs which are known to be present circulating in serum and plasma. This chapter also identifies the top molecular CNA characterisation techniques and technologies which are used to identify and measure CNAs.

Since the discovery of circulating nucleic acids in plasma in 1948, many diagnostic applications have emerged. For example, diagnostic and prognostic potentials of circulating tumor - derived DNA have been demonstrated for many types of cancer.

The parallel development of fetal - derived DNA detection in maternal plasma has opened up the possibility of non - invasive prenatal diagnosis and monitoring of many pregnancy - associated disorders. This is the subject of a distinct report also available from Veracity Health.

ES.3 Market Revenue Analysis: Non-invasive Prenatal Diagnostics

An analysis of the revenues and forecasts for the global non-invasive prenatal diagnostics (NIPD) market with a further more detailed analysis and forecast of the revenues for the global market sub-divided by major market sub-segments by geographic region and finally by selected country. This chapter also reviews the principle market drivers and restraints affecting and influencing the development of this market.

Please note that with the exception of North America each of the geographic regions analyzed include other remaining countries in these geographic regions. For the purposes of clarity within this report although these other individual countries in these geographic regions have been analyzed the market values and market shares have not been included. Should the reader require more detailed information about these countries the author of this report will be able to provide a customized report providing the additional information that would be required.

Veracity Health has determined that the global market was almost non-existent as products had not been available commercially in 2010.

By the year 2013 a number of commercially available products had entered the market driving the global market to an estimated value of $329.6 million. By using a proprietary forecast spreadsheet which took into account the market variables it is predicted that by 2020 the market is set to grow to $2.61 billion (CAGR of 34.4%).

The valuation of the market reflects the changes to the economic, demographic and market variables which are affecting the value of the market. These include the:

  • predicted relative decrease in product pricing as the market matures and as new lower priced products enter the market over the forecast period,
  • Impact of the greater access and acceptability of non-invasive prenatal diagnostic testing in preference to the traditional methods such as amniocentesis.
  • impact of the current global recession and its effect on the funding of national healthcare systems and specifically the diagnostics services within each national state.

ES.4 Market Share Analysis: Non-invasive Prenatal Diagnostics

Exhibit E.S.1 provides a summary of the market shares for the global non-invasive prenatal diagnostics (NIPD) market in 2013.

The global market is dominated by 5 major suppliers i.e. Sequenom, Inc, Ariosa Diagnostics, BGI Diagnostics (Division of BGI), Natera and Verinata Health (Illumina). These top 5 suppliers accounted for an estimated 92.9% of the global market in 2013 with the market leader Sequenom, Inc holding a 40.6% share of the market.

In addition a number of smaller companies such as, Ravgen, Cellular Research and Trovagene are emerging who could challenge the market leadership positions of the current leading suppliers.

image1

image2

ES.5 Company Profiles

This chapter provides the profiles of the leading 9 companies involved in the research and development, manufacture and marketing of devices which incorporate the technologies used for the detection of CNAs used in prenatal diagnostics. It provides a review of their historical development, key product areas including products in developments as well as short reviews of their key proprietary technologies.

Table of Contents

Executive Summary

  • ES.1 Introduction to the Non-invasive Prenatal Diagnostics Market
  • ES.2 Background to Circulating Nucleic Acids
  • ES.3 Market Revenue Analysis: Non-invasive Prenatal Diagnostics
  • ES.4 Market Share Analysis: Non-invasive Prenatal Diagnostics
    • Exhibit E.S. 1: Global Market Share Analysis - Non-invasive Prenatal Diagnostic Products (2013)
    • Exhibit E.S. 2: Global Market Share Analysis - Non-invasive Prenatal Diagnostic Products (2013)
  • ES.5 Company Profiles

1.1 Background to the Report

  • 1.2 Report Objectives and Deliverables
  • 1.3 Methodology

2.1 Introduction to Circulating Nucleic Acids (CNAs)

  • Exhibit 2.1: Major Developments in Understanding Nucleic Acids and their Cellular Roles
  • Exhibit 2.2: Circulating DNA Concentrations in Blood of Healthy Donors and Selected Cancer Patients

2.2 Categories of Circulating Nucleic Acids

  • 2.2.1 Circulating Cell-Free DNA
  • 2.2.2 Circulating Extracellular DNA
  • 2.2.3 RNA.
    • 2.2.3.1 microRNAs (miRNAs)
    • 2.2.3.2 miRNA Mimics and Inhibitors
    • 2.2.3.3 Small Interfering RNA (siRNA)
    • 2.2.3.4 RNA Interference (RNAi)

2.3 Circulating Nucleic Acids as a Diagnostic Tool

  • 2.3.1 Circulating DNA as a Biomarker of Cancer
  • 2.3.2 Use of Circulating DNA for Prenatal Diagnosis
  • 2.3.3 Circulating RNA as a Biomarker of Cancer
    • Exhibit 2.3: Circulating Tumour-Associated miRNAs as potential biomarkers in Lung Cancer
    • Exhibit 2.4: Circulating Tumour-Associated miRNAs as potential biomarkers in Breast Cancer
    • Exhibit 2.5: Circulating Tumour-Associated miRNAs as potential biomarkers in Prostate Cancer
    • Exhibit 2.6: Circulating Tumour-Associated miRNAs as potential biomarkers in Ovarian Cancer
    • Exhibit 2.7: Circulating Tumour-Associated miRNAs as potential biomarkers in Bladder Cancer
    • Exhibit 2.8: Circulating Tumour-Associated miRNAs as potential biomarkers in Pancreatic Cancer
    • Exhibit 2.9: Circulating Tumour-Associated miRNAs as potential biomarkers in Gastric Cancer
    • Exhibit 2.10: Circulating Tumour-Associated miRNAs as potential biomarkers in Liver Cancer
    • Exhibit 2.11: Circulating Tumour-Associated miRNAs as potential biomarkers in Colo-Rectal Cancer
    • Exhibit 2.12: Circulating Tumour-Associated miRNAs as potential biomarkers in Oral Cancer
    • Exhibit 2.13: Circulating Tumour-Associated miRNAs as potential biomarkers in Esophageal Cancer
  • 2.3.4 Circulating RNA in Pregnancy

2.4 Methods Used for the Detection of Circulating Nucleic Acids

  • Exhibit 2.14: Top molecular CNA Characterisation Techniques
  • Exhibit 2.15: Top molecular CNA Characterisation Techniques

3.1 Introduction

3.2 Market Dynamics

  • 3.2.1 Market Drivers
    • 3.2.1.1 Significant Advantages of Conventional Prenatal Screening and Diagnostic Methods
    • 3.2.1.2 Significant Endorsement for NIPD
    • 3.2.1.3 Recognised Benefits Associated with NIPD
  • 3.2.2 Market Restraints
    • 3.2.2.1 Ethical Challenges in Providing Noninvasive Prenatal Diagnosis
    • 3.2.2.2 Specific Reimbursement and Accessibility Issues
    • 3.2.2.3 Specific Identified Limitations of NIPD

3.3 Selected Non-invasive Prenatal Diagnostic Products

  • Exhibit 3.1: Featured Non-invasive Prenatal Diagnostic Products

3.4 Market Revenue Analysis

  • 3.4.1 Global Market Revenue Analysis
  • 3.4.2 Global Market Revenue Analysis by Geographic Region
    • Exhibit 3.2: Global Market Revenue Forecast - Non-invasive Prenatal Diagnostic Products (2010 2020)
    • Exhibit 3.3: Global Market Revenue Forecast - Non-invasive Prenatal Diagnostic Products (2010 2020)
    • Exhibit 3.4: Market Revenue Forecast by Geographic Region - Non-invasive Prenatal Diagnostic Products (2010 - 2020)
    • Exhibit 3.5: Percentage Share of Global Market Revenue Forecast by Geographic Region - Non-invasive Prenatal Diagnostic Products (2010 - 2020)
    • Exhibit 3.6: Percentage Share of Global Market Revenue Forecast by Geographic Region - Non-invasive Prenatal Diagnostic Products (2010 - 2020)
  • 3.4.3 Market Revenue Analysis by Selected Country
    • Exhibit 3.7: Market Revenue Forecast by Selected Countries - Non-invasive Prenatal Diagnostic Products (2010 - 2020)
    • Exhibit 3.8: Market Revenue Forecast by Selected Countries - Non-invasive Prenatal Diagnostic Products (2010 - 2020)

4.1 Market Share Analysis

  • 4.1.1 Global Market Share Analysis
    • Exhibit 4.1: Global Market Share Analysis - Non-invasive Prenatal Diagnostic Products (2013)
    • Exhibit 4.2: Global Market Share Analysis - Non-invasive Prenatal Diagnostic Products (2013)
  • 4.1.1 Market Share Analysis by Geographic Region
    • Exhibit 4.3: Market Share Analysis by Geographic Region (2013)
  • 4.1.2 Market Share Analysis by Selected Country
    • Exhibit 4.4: Market Share Analysis by Selected Country - Non-invasive Prenatal Diagnostics (2013)

5.1 Sequenom Inc

  • Exhibit 5.1: Sequenom, Inc., Revenues by Business Segment ($ millions) 2013-2011

5.2 Ariosa Diagnostics

5.3 Natera Inc

5.4 LifeCodexx AG

5.5 Verinata Health, Inc (Illumina, Inc)

  • Exhibit 5.2: Illumina, Inc., Revenues by Business Segment ($ thousands) 2013-2011

5.6 Berry Genomics Co., Ltd

5.7 BGI Diagnostics (Division of BGI)

5.8 CellScape

5.9 Kellbenx

Glossary of Acronyms

Back to Top